-
PDF
- Split View
-
Views
-
Cite
Cite
Gabriela A Garcia, Tharanga N Kariyawasam, Anton R Lord, Cristiano Fernandes da Costa, Lana Bitencourt Chaves, Josué da Costa Lima-Junior, Rafael Maciel-de-Freitas, Maggy T Sikulu-Lord, Malaria absorption peaks acquired through the skin of patients with infrared light can detect patients with varying parasitemia, PNAS Nexus, Volume 1, Issue 5, November 2022, pgac272, https://doi.org/10.1093/pnasnexus/pgac272
- Share Icon Share
Abstract
To eliminate malaria, scalable tools that are rapid, affordable, and can detect patients with low parasitemia are required. Non-invasive diagnostic tools that are rapid, reagent-free, and affordable would also provide a justifiable platform for testing malaria in asymptomatic patients. However, non-invasive surveillance techniques for malaria remain a diagnostic gap. Here, we show near-infrared Plasmodium absorption peaks acquired non-invasively through the skin using a miniaturized hand-held near-infrared spectrometer. Using spectra from the ear, these absorption peaks and machine learning techniques enabled non-invasive detection of malaria-infected human subjects with varying parasitemia levels in less than 10 s.
We provide a report of the application of the near-infrared spectroscopy (NIRS) technique and machine learning algorithms for non-invasive and reagent-free detection Plasmodium vivax and Plasmodium falciparum infected patients with varying parasitemia levels. The technique involves a 5 to 10 s interaction of harmless infrared light with the skin of human subjects and subsequent collection of a diagnostic spectral signature. NIRS is portable, results can be achieved in real time and it has the capacity to screen thousands of people in a day without consuming any reagents. It is an ideal surveillance tool for screening a large population of people to identify infected populations with minimal cost and time and can easily be scaled up to guide current malaria elimination strategies.
Introduction
In 2021, the World Health Organization (WHO) estimated that 241 million malaria-related cases and 627,000 malaria-related deaths occurred in 2020 [1]. The Plasmodium parasites that cause the disease are transmitted to people by bites of infected female Anopheles mosquitoes. Among them, the two major Plasmodium parasite species are Plasmodiumfalciparum and P. vivax. In 2020, P. falciparum accounted for 98% of estimated malaria cases globally and 99.7% of the cases were reported in the WHO African region. In the WHO region of Americas, P. vivax is the predominant parasite representing 68% of malaria cases in the region [1]. In 2015, WHO set a strategy to guide countries toward malaria elimination by reducing global malaria incidences and mortality by at least 90% and eliminating malaria in at least 35 countries by the year 2030 [2]. One of the pillars on which this strategy is based on is to ensure universal access to malaria prevention, diagnosis, and treatment. To achieve this target, WHO recommends universal testing of all suspected cases of malaria. This is particularly crucial in endemic areas where a majority of the malaria-infected population can be asymptomatic [3] as well as in low malaria transmission settings where the proportion of asymptomatic population among the infected individuals can be as high as 60% [4]. Universal testing is expected to prompt and facilitate the treatment of asymptomatic population to limit further community transmission.
Optical microscopy, rapid diagnostic tests (RDTs), and molecular tests are the three main diagnostic techniques currently available for malaria diagnosis. Microscopy is the traditional way of detecting malaria parasites in stained thick or thin peripheral blood films using Giemsa, Wright’s, or Field’s stains. Thick blood films are used to detect the presence of malaria parasite, whereas thin blood films are often used to confirm the Plasmodium species [5]. It is the most widely used technique for malaria diagnosis due to its low cost, simplicity, and its capacity to detect parasites, differentiate Plasmodium species, and estimate the parasite concentration. However, microscopy is technically demanding, time-consuming, and requires specialized expertise to accurately identify parasites and differentiate species in samples with low parasitemia or samples with mixed infections [6–8]. As the average microscopist detection limits are estimated to be 50 to 100 parasites/µL, the likelihood of underestimating infection rates particularly in low transmission settings or among asymptomatic population where parasitemia is low has been reported [9]. Microscopy is also often unavailable in rural settings where power supply can be problematic [10].
RDTs detect malaria antigens in blood by targeting Plasmodium-specific proteins such as histidine-rich protein II (HRP-II) or lactate dehydrogenase (LDH) [11, 12]. RDTs are simple, relatively cheap, and can be used in remote areas without specialized equipment or need for electricity. However, RDTs can only reliably detect 50 to 100 parasites/µL [11, 12], they have to be coupled with other techniques in areas where more than one malaria parasite species is present due to their inability to differentiate Plasmodium species [9, 13], and they can generate false positives due to the persistence of HRP-II following an infection [14].
Molecular tests such as polymerase chain reaction (PCR) are currently the most accurate and the most sensitive techniques for detecting malaria in low- or sub-microscopic samples, for mixed infections, and for differentiating Plasmodium species [15–17]. However, molecular techniques are costly, time-consuming, and require skilled expertise [18]. In addition, none of these traditional techniques are equipped for large-scale surveillance of malaria cases in endemic countries.
Here, we explored the potential of a miniaturized near-infrared spectrometer that could easily be scaled up for universal surveillance of malaria cases to guide the proposed WHO malaria elimination strategy. The near-infrared spectroscopy (NIRS) is a simple to use, non-invasive, reagent-free technique that uses the near-infrared part of the electromagnetic spectrum to characterize biological samples. It involves shining a beam of light on a sample for approximately 5 s and subsequent collection of a spectral signature. The spectral signature is a reflection of the chemical composition of a sample and can be analyzed using machine learning algorithms to identify diagnostic features. We hypothesized that the presence of malaria parasites in red blood cells can produce unique infrared signatures that could potentially be used for diagnosis of malaria. We used a handheld spectrometer to non-invasively collect spectral signatures from the right and left ears, arms, and fingers of malaria-positive and -negative individuals living in a malaria-endemic area in Brazil where both P. falciparum and P. vivax are prevalent at a 30%/70% ratio.
Materials and Methods
Study area, population, and malaria prevalence
The study was conducted in the municipality of São Gabriel da Cachoeira (SGC), located in the Upper Rio Negro region, State of Amazonas, northern Brazil (0°07′51′′S; 67°05′15′′W). SCG is surrounded by the Amazon and is the municipality with the highest percentage of self-declared indigenous people (over 75%) in Brazil, with an estimated 30,000 people living in the area, and over 20 ethnic groups [19]. The Amazon region represents 99.8% of all malaria cases in Brazil and cases of both P. vivax and P. falciparum have been recorded. In 2019, a total of 8,605 cases were reported in SCG, and from January 2019 to June 2020, an estimated 34% of malaria cases were caused by P. falciparum and mixed infections [20].
Ethics approval
The study was approved by the human ethics committee of Instituto Oswaldo Cruz (Ethics Protocol No. 94,070,418.7.0000.5248). Patients with malaria symptoms who were seeking diagnosis and treatment at the basic health units were approached to volunteer for this study. Prior to recruitment, a written informed consent was obtained from patients after the nature and possible consequences of the studies were explained. The written consent form was previously approved by human ethics committee at Fiocruz. Further work to determine presence of malaria parasites in volunteer’s blood was approved by the National Genetic Heritage Management System (A88B262).
NIRS instrument used
NIRvascan near-infrared spectrometer reflective model G1 (Allied Scientific Pro, Canada) was used in this study (Fig. 1). The model used is a diffuse reflectance spectrometer with wavelength ranging from 900 to 1700 nm, a 5000:1 signal-to-noise ratio, and an optical resolution of 10 nm pixel resolution. It has an inGaAs detector (Hamamatsu model G12180-010A), a dark current of 0.8nA @VR = 1 V, noise equivalent power of 1.4 × 1014 @λp, and a light source with two integrated tungsten halogen lamps of 1 W, built-in at 45° from the surface. It weighs 136 g and measures 82.2 × 63 × 40 mm. The spectrometer is rechargeable and can be operated by either a computer or a smartphone via Bluetooth.

An illustration of non-invasive scanning of the finger and the arm with the NIRvascan spectrometer (A) and reflective spectrum produced from the scanning (B).
Scanning
Participants presenting with malaria symptoms were scanned with the NIRvascan spectrometer, which was connected to a notebook using Bluetooth. The participants left and right arm, ear, and finger were one after the other placed directly onto the spectrometer’s scan window and spectra was collected by pressing the scan button. Two spectra were collected from each body part scanned. A total of 60 patients were scanned and a total of 360 spectra were collected. In addition, 1 mL of whole blood was collected intravenously from each patient into EDTA tubes and stored for microscopy and PCR. Patient metadata, including gender, age, weight, skin color, and height were also recorded. An example of a raw spectrum collected by the NIRvascan spectrometer is shown in Fig. 1.
Gold standard microscopy and PCR confirmation of malaria-positive and malaria-negative cases
To validate NIR technique’s capacity to differentiate infected from uninfected subjects, differentiate Plasmodium species and determine parasitemia level of subjects, the WHO gold standard technique of blood films, and microscopy was used.
Blood films were read by at least two microscopists. Readings were averaged, and quality assurance was provided by a WHO Level 1 certified malaria microscopist. Microscopy results were grouped into four levels of parasitemia groups; high parasitemia (>100,000 parasites/µL); moderate parasitemia (10,000 to 100,000 parasites/µL); low parasitemia (500 to 10,000 parasite/µL); and very low parasitemia (300 to 500 parasites/µL).
The infection status and Plasmodium species type were further confirmed by standard PCR. Genomic DNA from whole blood samples were extracted using the QIAamp DNA Blood Mini Kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany) and stored at −20°C until amplification. Detection and identification of Plasmodium species was performed using Nested PCR with specific primers for genus (Plasmodium sp.) and species (P. falciparum and P. vivax) as described by Snounou et al. [21, 22]. In the first amplification reaction, 3 μL of purified genomic DNA were used in a 25 μL reaction with genus specific primers. During the second PCR reaction, 3 μL of PCR amplification product of the first reaction was used as a template in a 25 μL reaction with species specific primers. The amplified PCR products were size-fractionated by electrophoresis in 2% agarose gel (Sigma Aldrich, Missouri, MO, USA), 1 × TAE buffer (0.04 M TRIS-acetate, 1 mM EDTA) in the presence of 1 × GelRed nucleic acid stain (Biotium, Fremont, CA, USA). PCR products were visualized by ultraviolet (UV) illumination. The species of Plasmodium were determined by species-specific amplicon sizes.
Data analysis
Savitzky-golay least-square filtering
To determine unique absorption peaks for malaria parasites, all spectra from malaria-infected subjects were averaged based on the body part scanned regardless of the Plasmodium species they were infected with and compared against averaged spectra of uninfected subjects. To identify absorption peaks for P. falciparum and P. vivax, raw spectra of each species were averaged separately.
Machine learning
Raw spectral signatures were organized in MS Excel spreadsheet before they were imported for analysis using JMP version 16.2 software (SAS institute, North Carolina, NC, USA). Data in excel spreadsheet were classified according to patient ID, infection status, parasitemia level, and Plasmodium species type.
In JMP, supervised machine learning was used to analyze the data. Data from infected patients were pooled regardless of the Plasmodium parasite they were infected with, their parasitemia level and the body part scanned. This allowed us to assess the capacity of NIRS to differentiate malaria infected from uninfected subjects regardless of their parasitemia level. As there was not enough P. falciparum infected samples to train a model for predicting Plasmodium species, we did not attempt to differentiate patients infected with P. vivax from those infected with P. falciparum. Spectra was first divided into a training set consisting 60% of all the data containing 216 spectral signatures from 16 malaria-positive and 20 malaria-negative subjects and the resultant model was used to predict an independent set of 11 malaria-positive and 13 malaria-negative subjects. We applied the model screening feature to simultaneously fit several machine learning algorithms, including Support Vector Machines, Decision Tree, K Nearest Neighbors, Bootstrap Forest, Boosted Tree, Discriminant, Logistic Regression, Artificial Neural Network (ANN), and Fit Stepwise on the data to allow us to compare and select the best predictive model for infection prediction using unique spectral peaks identified. Malaria infection status was used as the response factor and the identified unique spectral signatures for malaria, skin color, age, height, weight, body part scanned, and gender were used as predictors. The best predictive model selected for differentiating infected from uninfected samples was ANN. The ANN networks were fully connected, consisting of an input layer with the prior identified unique peaks, and an output layer. Activation between nodes was performed using the TanH function. The output layer was trained as a binary outcome (e.g., infected vs. uninfected). The resultant model was applied to predict individuals that were left out of the model.
Results
Results from PCR confirmed 45% (N = 27) of the 60 people scanned were positive with malaria, while the rest were malaria negative. Of the malaria-positive individuals, 75% (N = 20) and 25% (N = 7), were infected with P. vivax and P. falciparum, respectively. Results from microscopy indicated that out of the 27 infected patients, 7.4% (2 subjects) had extremely high parasitemia, 18.5% (5 subjects) had moderate parasitemia, 44.4% (12 subjects) had low parasitemia, and 29.6% (8 subjects) had very low parasitemia. Malaria positive and negative groups consisted of 60% and 66% women, respectively. Of those subjects that were malaria positive, their age ranged between 19 and 73 y old with 66% of them ≤40 y old whereas the age of the malaria-negative subjects ranged from 20 to 75 y old with 55% of them ≤40 y old. Out of the total, 70% of malaria-negative subjects and 80% of malaria-positive subjects weighed under 70 kg.
Raw absorbance spectra
Absorption differences were seen from the raw spectra collected from malaria-positive and malaria-negative patients. Malaria-positive patients were generally seen to have higher absorbance values than malaria-negative patients. Similarly, patients with P. falciparum generated spectra with higher absorbance values relative to those that were infected with P. vivax (Fig. 2).

Raw average spectra of (A) malaria-positive and malaria-negative subjects irrespective of the Plasmodium species they were infected with and (B) P. falciparum and P. vivax infected patients.
Absorption peaks for malaria-infected patients
Using the second derivative spectra of the ear, finger, and arm, absorption differences between malaria-positive and malaria-negative subjects were observed (Fig. 3). Spectra from the ear produced the most distinct bands whereas less distinct bands were seen from spectra collected from the arm. Distinct absorption peaks for malaria-positive patients were observed within the 1st to 3rd overtone regions and these bands were present in at least two body parts scanned. They include absorption peaks around 937, 1120, 1160, 1200, 1300, 1370, 1407, 1516, 1538, 1560, 1607, and 1660 nm (Fig. 3). Among them, those that were reduced in malaria-infected patients include peaks around 977, 1160, 1205, 1407, and 1516 nm whereas absorption peaks that increased in malaria-infected patients include those around 1120, 1300, 1538, 1560, and 1607 nm. Peaks in the second overtone region are dominated by overtones of O–H, N–H, and C=H combinations whereas the absorption peaks around 1400 to 1660 nm in the first overtone region are dominated by C=H and O–H compounds related to parasite proteins (Table 1).

Second derivative spectra showing absorption peaks for malaria positive (red line) and negative (blue line) individuals collected from the ear (A), finger (B), arm (C), and purified P. falciparum (D). Spectra presented for A to C is an average of 27 infected subjects and 33 negative subjects.

Second derivative spectra showing absorption peaks for P. falciparum (red line) and P. vivax (blue line) for the spectra collected from the ear (A), finger (B), and arm (C). Spectra shown is an average of 7 P. falciparum and 20 P. vivax infected subjects.
Peak identified* . | Bond vibration . | Structure . |
---|---|---|
930,937 | C–H third overtone | CH3 |
1121,1127 | C–H second overtone | Lipids |
1154,1160,1170 | C–H stretch second overtone | CH3 groups |
1192,1205 | C–H stretch second overtone | CH3, Hemoglobin |
1302,1309 | C–H overtones and combinations | Fats/oils |
1356,1368, 1370,1377 | C–H stretch first overtone | CH3 groups |
1407,1413, 1421,1431 | O–H first overtone | ROH Oil |
1516,1519 | N–H stretch first overtone | Protein |
1530,1538 | O–H stretch first overtone N–H | Starch |
1560,1569 | N=H stretch first overtone | CONH |
1607 | N=H stretch first overtone | |
1636,1640, 1642 | N=H stretch first overtone | Malaria hemozoin protein |
1658,1660 | C–H first overtone | Polyunsaturated fatty acid |
Peak identified* . | Bond vibration . | Structure . |
---|---|---|
930,937 | C–H third overtone | CH3 |
1121,1127 | C–H second overtone | Lipids |
1154,1160,1170 | C–H stretch second overtone | CH3 groups |
1192,1205 | C–H stretch second overtone | CH3, Hemoglobin |
1302,1309 | C–H overtones and combinations | Fats/oils |
1356,1368, 1370,1377 | C–H stretch first overtone | CH3 groups |
1407,1413, 1421,1431 | O–H first overtone | ROH Oil |
1516,1519 | N–H stretch first overtone | Protein |
1530,1538 | O–H stretch first overtone N–H | Starch |
1560,1569 | N=H stretch first overtone | CONH |
1607 | N=H stretch first overtone | |
1636,1640, 1642 | N=H stretch first overtone | Malaria hemozoin protein |
1658,1660 | C–H first overtone | Polyunsaturated fatty acid |
Peak identified* . | Bond vibration . | Structure . |
---|---|---|
930,937 | C–H third overtone | CH3 |
1121,1127 | C–H second overtone | Lipids |
1154,1160,1170 | C–H stretch second overtone | CH3 groups |
1192,1205 | C–H stretch second overtone | CH3, Hemoglobin |
1302,1309 | C–H overtones and combinations | Fats/oils |
1356,1368, 1370,1377 | C–H stretch first overtone | CH3 groups |
1407,1413, 1421,1431 | O–H first overtone | ROH Oil |
1516,1519 | N–H stretch first overtone | Protein |
1530,1538 | O–H stretch first overtone N–H | Starch |
1560,1569 | N=H stretch first overtone | CONH |
1607 | N=H stretch first overtone | |
1636,1640, 1642 | N=H stretch first overtone | Malaria hemozoin protein |
1658,1660 | C–H first overtone | Polyunsaturated fatty acid |
Peak identified* . | Bond vibration . | Structure . |
---|---|---|
930,937 | C–H third overtone | CH3 |
1121,1127 | C–H second overtone | Lipids |
1154,1160,1170 | C–H stretch second overtone | CH3 groups |
1192,1205 | C–H stretch second overtone | CH3, Hemoglobin |
1302,1309 | C–H overtones and combinations | Fats/oils |
1356,1368, 1370,1377 | C–H stretch first overtone | CH3 groups |
1407,1413, 1421,1431 | O–H first overtone | ROH Oil |
1516,1519 | N–H stretch first overtone | Protein |
1530,1538 | O–H stretch first overtone N–H | Starch |
1560,1569 | N=H stretch first overtone | CONH |
1607 | N=H stretch first overtone | |
1636,1640, 1642 | N=H stretch first overtone | Malaria hemozoin protein |
1658,1660 | C–H first overtone | Polyunsaturated fatty acid |
Absorption peaks for P. falciparum and P. vivax
Similarly, spectra from the ear produced the most distinct peaks for P. falciparum and P. vivax. The second derivative spectra of P. falciparum and P. vivax infected patients from the ear indicates that across the entire spectrum, distinct peaks for patients with P. falciparum parasites and P. vivax were around 960,1170, 1413,1474, 1569, 1538, and 1642 nm. When the ear was scanned, peaks at 960,1170, 1413, and 1538 nm were observed and these peaks were reduced in P. vivax infected subjects. Contrary, when the finger was scanned, peaks at 960 and 1474 nm increased in absorbance in P. vivax infected patients. The absorption peaks observed for the two species were also responsible for differentiating infected from uninfected subjects (see Fig. 3). Table 1 shows an average of all peaks identified that could be related to the presence of Plasmodium parasites.
Change of absorption peaks with parasitemia
The absorbance peaks of infected subjects were compared against parasitemia levels as well as against peaks from malaria-negative subjects. The absorbance at 960 nm was lowest and highest for patients with very high parasitemia and malaria-negative patients, respectively. The absorption peaks at 1110 and 1290 nm were highest for patients with very low parasitemia but lowest for subjects that were malaria negative whereas the peak at 1180 nm was lowest for subjects with very low parasitemia but highest for malaria-negative patients. Generally, absorption peaks were stable across patients with low and high parasitemia (Fig. 5).

Absorption peaks of malaria-positive subjects with varying parasitemia relative to malaria-negative subjects using average spectra collected from the ear for a peak at 960 nm (A) and peaks at 1110,1180, and 1290 nm (B).
Sensitivity, specificity, and accuracy of NIRS
We tested on a preliminary scale whether the identified absorption peaks could predict infected and uninfected subjects using ANN machine learning models. Spectra collected from the ear produced the most accurate prediction of infection in the independent subjects with an accuracy of 92% (N = 24), sensitivity of 100% (N = 11) and specificity of 85% (N = 13). Moreover, sensitivity was 100% across all parasitemia levels. Sensitivity and specificity were similar between replicate body parts scanned indicating the spectra was collected with minimal errors between the left and right body parts. Comparatively, the accuracy, sensitivity, and specificity of the spectra collected from the finger was 70% (N = 24), 72 (N = 11), and 69% (N = 13), respectively, whereas spectra of the arm resulted into a predictive accuracy of 72% (N = 24), sensitivity of 59% (N = 11), and specificity of 85% (N = 13). Figure 6 shows a summary of the differentiation of infected and uninfected patients based on the spectra of the ear alone.

Results of the ANN model used to differentiate infected and uninfected subjects who were used to validate the model. Each circle represents one subject and results shown are for scans of the left ear (ear1) and the right ear (ear2) of each patient.
Discussion
We assessed whether a rapid, non-invasive, and reagent-free technique that uses the near-infrared region of the electromagnetic spectrum could produce unique malaria spectral signatures and if those signatures could be applied to predict malaria infection status in human subjects. The spectral signatures collected from 27 malaria-positive individuals, regardless of (1) their parasitemia level and (2) whether they were positive with P. falciparum or P. vivax, were seen to be different from signatures of the 33 malaria-negative individuals. The spectra from the ear produced the most distinct bands for the two groups. Similarly, remarkable albeit few differences were observed for spectral signatures of subjects that were infected with P. falciparum and P. vivax indicating their chemical profile could be different. When these unique signatures were applied to differentiate infected from uninfected subjects, sensitivity of 100% and accuracy of 92% were achieved using spectra collected from the ears.
We hypothesized that the invasion of Plasmodium parasites into the human host’s red blood cells results in significant structural, biochemical, and functional changes that generate unique infrared absorption peaks for malaria-positive and -negative individuals. This include the loss of the discoid shape of the red blood cells, reduced hemoglobin concentration, increased adhesiveness and permeability to Plasmodium species infection [26]. In addition, over 400 Plasmodium parasite-related proteins, including the commonly used biomarker for malaria infection, i.e., the hemozoin protein, hydroxy fatty acids, and lipids, are released into red cells [27–29]. These molecules can absorb light at specific wavelengths to generate unique absorption bands that could be used as biomarkers for malaria infection (Fig. 3). We also tested whether P. vivax and P. falciparum cause remarkable differences to host red cells resulting into a unique NIR spectrum. For example, it has been reported that an infection with P. vivax results in enlarged, pale, fine stippling parasitized red cells known as Schuffener’s dots [30], whereas infection with P. falciparum results in fine stippling non-enlarged parasitized cells known as Maurer’s clefts [ 31]. There are also remarkable genomic and structural differences between schizonts, trophozoites, and gametocytes of the two species that are expected to generate unique infrared spectral signatures [32].
The infrared absorption peaks for malaria identified in this study through non-invasive scanning were consistent with peaks observed when pure P. falciparum parasites were scanned (Fig. 3D). The peaks in our study were also consistent with peaks reported by two previous studies that used NIRS to detect P. falciparum and hemoglobin in red blood cells in vitro [33, 34]. To our knowledge, this is the first study to report unique NIR absorption peaks for malaria parasites acquired non-invasively through the skin of human subjects with diagnostic features. Our previous NIR studies have indicated that the technique can also non-invasively detect other infections in mosquitoes such as malaria [35], Zika [36], Wolbachia [37], and chikungunya [38]. NIRS has also been used to detect cancer tumors in patients [39–41].
When Plasmodium parasites consume hemoglobin in red blood cells, they produce a toxic compound known as heme. Heme is detoxified by the parasite into hemozoin pigment through metabolization of hemoglobin. Hemozoin is therefore considered a powerful and reliable biomarker for malaria infection. Using second derivative average spectra of malaria-positive and malaria-negative patients, we observed several bands that have previously been reported as hemozoin absorption bands. Figure 3 shows absorption bands around 1505 to 1560 nm, 1636 to 1642 nm, and 1515 nm previously observed from synthetic hemozoin (β-hematin) and dry hemozoin isolated from infected red blood cells [33]. Absorption bands around 1205, 1431, and 1642 nm in the second overtone region are related to hemoglobin as reported by Kuenstner and Norris [34] and more recently by Adegoke and colleagues [33]. Absorption bands around 1432 and 1388 nm were observed when pure P. falciparum parasites were scanned (Fig. 3D). In this study, hemoglobin bands around 1205 nm and bands around 1400 to 1431 nm were reduced in malaria positive individuals. A reduction in hemoglobin concentration is expected for a malaria-infected patient as the presence of the malaria parasite consumes hemoglobin and other red blood cell proteins to produce heme.
Current malaria elimination strategies require high-throughput approaches that can facilitate cost-effective, rapid, and large-scale surveillance of malaria cases. Here, we have identified unique peaks for malaria parasites and have gone a step further to show that the peaks could differentiate infected from uninfected malaria subjects with low and extremely high parasitemia providing the first evidence of the potential use of an affordable, light-based technology for rapid and non-invasive surveillance of malaria in large-scale programmatic studies. By removing the need to draw blood, non-invasive surveillance of malaria by NIRS has the potential to revolutionize our ability to rapidly detect malaria in large-scale human populations and facilitate timely treatment to reduce further transmission. With a sensitivity of 100% achieved at very low parasitemia, NIRS could enable rapid large-scale screening of communities to identify asymptomatic patients and make malaria diagnosis among babies a painless undertaking. Following the development of predictive models, NIRS could enable thousands of individuals to be screened in a day with unskilled personnel. Furthermore, the spectrometer used for this study allows cloud-based prediction for real-time monitoring of malaria infections among large-scale community groups and in multiple locations including in rural areas. Cloud-based and real-time surveillance means data will be available to decision-makers in real time, thereby facilitating rapid decision-making and timely distribution of resources where required to stop further transmission and outbreaks.
Furthermore, NIRS is a unique tool that could facilitate timely isolation and treatments of infected cases, through mass screening of populations at risk, including at ports of entry such as airports or even at household levels, to stop transmission to local mosquito populations by overseas travellers, reduce global outbreaks, and prevent reintroduction in areas under elimination. The NIRS unit that was assessed under this study is an off-the-shelf spectrometer that could easily be integrated and scaled up into existing programmatic malaria epidemiological surveillance programs. However, further work is recommended on a larger scale in multiple malaria epidemiological settings to develop robust predictive models. Factors such as malaria species type, asymptomatic malaria cases, age groups, blood groups, skin color, and most importantly the presence of mixed/co-infections of malaria species or other pathogens should be considered in future studies for developing robust malaria-specific predictive models. Future work should also assess the capacity of the tool to quantify parasitemia of infected individuals and ability to differentiate subjects infected with different Plasmodium species.
In conclusion, our proof-of-concept study provides insights into the potential application of NIRS and machine learning techniques for rapid, non-invasive, and large-scale surveillance of malaria and potentially other human pathogens.
ACKNOWLEDGEMENTS
We thank Aline Tatila-Ferreira, Lilha M.B. dos Santos, and Edson Dantas for technical support.
Funding
The work was funded by Fiocruz INOVA Ideias Inovadoras, Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Advance Queensland Industry Research Fellowship (AQIRF2018019 awarded to M.T.S.-L), and the NHMRC project grant (APP1159384 awarded to M.T.S.-L).
Authors' Contributions
G.A.G.: study design, human data collection, and PCR test; T.N.K.: data curation; A.R.L.: study design and model design; C.F.C., L.B.C., and J.C.L.-J.: study design and data collection; R.M-d-F.: study design and funding; and M.T.S.-L.: study design, data analysis, manuscript writing, and funding. All authors read and approved the final manuscript.
Data Availability
Anonymized patient data used in this study are available at https://doi.org/10.48610/e19e6fc.
Notes
Competing Interest: The authors declare no competing interest.
References
Author notes
R.M-d.-F. and M.T.S.-L. equally contributed to this work.